Advertisement
Australia markets closed
  • ALL ORDS

    8,012.10
    +1.60 (+0.02%)
     
  • AUD/USD

    0.6674
    +0.0001 (+0.02%)
     
  • ASX 200

    7,769.40
    -0.30 (-0.00%)
     
  • OIL

    81.60
    +0.03 (+0.04%)
     
  • GOLD

    2,352.90
    +6.00 (+0.26%)
     
  • Bitcoin AUD

    99,372.20
    +1,399.59 (+1.43%)
     
  • CMC Crypto 200

    1,375.82
    -6.84 (-0.49%)
     

Karyopharm to Participate at the Jefferies Global Healthcare Conference

NEWTON, Mass., May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Jefferies Global Healthcare Conference in a fireside chat on Wednesday, June 5, 2024 at 1:00 p.m. ET in New York, NY.

(PRNewsfoto/Karyopharm Therapeutics Inc.)
(PRNewsfoto/Karyopharm Therapeutics Inc.)

A live webcast of the event, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

ADVERTISEMENT

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-jefferies-global-healthcare-conference-302158124.html

SOURCE Karyopharm Therapeutics Inc.